18 June 2013
Keywords: b-ms/karo, bio, drop, obesity, drug, bristol-myers, squibb
Article | 01 April 2002
Bristol-Myers Squibb has discontinued the development of a thyroidhormone receptor modulator for obesity, derived from its joint research
program with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 April 2002
17 June 2013
© 2013 thepharmaletter.com